OBJECTIVE: To assess the effectiveness of the simplified medication adherence questionnaire (SMAQ) in identifying non-adherent patients. DESIGN: Prospective observational study of adherence. The six-item SMAQ was developed. The following aspects were evaluated: (i) criterion validity, comparison with electronic adherence monitoring; (ii) construct validity, association between adherence, as defined by the SMAQ, and virological outcomes; and (iii) reliability, internal consistency and reproducibility. PATIENTS: A group of 3004 unselected HIV patients who had initiated nelfinavir therapy combined with other antiretroviral drugs [21% naive, 15% protease inhibitor (PI)-naive, 64% PI-experienced] between January 1998 and December 1999 were enrolled in 69 hospitals in Spain. The SMAQ was administered at months 3, 6 and 12. RESULTS: The SMAQ showed 72% sensitivity, 91% specificity and a likelihood ratio of 7.94 to identified non-adherent patients, compared with the medication-event monitoring system (40 patients evaluated). At month 12, 1797 patients were evaluated, of whom 32.3% were defined as non-adherent; viral load < 500 copies/ml found in 68.3% of the adherent, and 46% of the non-adherent patients. A logistic regression analysis of PI-naive patients was performed, including age, sex, baseline viral load > 5 log10/ml, CD4 cell count < 200 x 10(6)/l, and non-adherence as independent variables. Non-adherence was the only significant risk factor in failing to achieve virological suppression. Cronbach's alpha internal consistency coefficient was 0.75, and overall inter-observer agreement was 88.2%. CONCLUSION: The SMAQ appears to be an adequate instrument with which to assess adherence in HIV-infected patients, and may be applied in most clinical settings.
OBJECTIVE: To assess the effectiveness of the simplified medication adherence questionnaire (SMAQ) in identifying non-adherent patients. DESIGN: Prospective observational study of adherence. The six-item SMAQ was developed. The following aspects were evaluated: (i) criterion validity, comparison with electronic adherence monitoring; (ii) construct validity, association between adherence, as defined by the SMAQ, and virological outcomes; and (iii) reliability, internal consistency and reproducibility. PATIENTS: A group of 3004 unselected HIVpatients who had initiated nelfinavir therapy combined with other antiretroviral drugs [21% naive, 15% protease inhibitor (PI)-naive, 64% PI-experienced] between January 1998 and December 1999 were enrolled in 69 hospitals in Spain. The SMAQ was administered at months 3, 6 and 12. RESULTS: The SMAQ showed 72% sensitivity, 91% specificity and a likelihood ratio of 7.94 to identified non-adherent patients, compared with the medication-event monitoring system (40 patients evaluated). At month 12, 1797 patients were evaluated, of whom 32.3% were defined as non-adherent; viral load < 500 copies/ml found in 68.3% of the adherent, and 46% of the non-adherent patients. A logistic regression analysis of PI-naive patients was performed, including age, sex, baseline viral load > 5 log10/ml, CD4 cell count < 200 x 10(6)/l, and non-adherence as independent variables. Non-adherence was the only significant risk factor in failing to achieve virological suppression. Cronbach's alpha internal consistency coefficient was 0.75, and overall inter-observer agreement was 88.2%. CONCLUSION: The SMAQ appears to be an adequate instrument with which to assess adherence in HIV-infectedpatients, and may be applied in most clinical settings.
Authors: Salvador Cabrera Figueroa; Alicia Iglesias Gómez; Almudena Sánchez Martín; María de la Paz Valverde Merino; Alfonso Domínguez-Gil Hurlé; Miguel Cordero Sánchez Journal: Clin Drug Investig Date: 2010 Impact factor: 2.859
Authors: Michael J Stirratt; Jacqueline Dunbar-Jacob; Heidi M Crane; Jane M Simoni; Susan Czajkowski; Marisa E Hilliard; James E Aikens; Christine M Hunter; Dawn I Velligan; Kristen Huntley; Gbenga Ogedegbe; Cynthia S Rand; Eleanor Schron; Wendy J Nilsen Journal: Transl Behav Med Date: 2015-07-09 Impact factor: 3.046
Authors: Natalia Mena-Vazquez; Sara Manrique-Arija; Lucía Yunquera-Romero; Inmaculada Ureña-Garnica; Marta Rojas-Gimenez; Carla Domic; Francisco Gabriel Jimenez-Nuñez; Antonio Fernandez-Nebro Journal: Rheumatol Int Date: 2017-06-19 Impact factor: 2.631
Authors: S B Mannheimer; R Mukherjee; L R Hirschhorn; J Dougherty; S A Celano; D Ciccarone; K K Graham; J E Mantell; L M Mundy; L Eldred; Michael Botsko; R Finkelstein Journal: AIDS Care Date: 2006-10
Authors: Benjamin A Toll; Sherry A McKee; Daniel J Martin; Peter Jatlow; Stephanie S O'Malley Journal: Nicotine Tob Res Date: 2007-05 Impact factor: 4.244
Authors: Miguel Angel Rodríguez Chamorro; Emilio García-Jiménez; Pedro Amariles; Alfonso Rodríguez Chamorro; María José Faus Journal: Aten Primaria Date: 2008-08 Impact factor: 1.137